Aurobindo gets USFDA nod for cancer-treatment injection

Aurobindo Pharma Ltd on Tuesday announced its wholly-owned arm Eugia Pharma Specialities has received a final approval from the US health regulator for its generic version of Plerixafor injection indicated for patients with certain types of cancer to prepare them for stem cell transplant.

The approval granted by the US Food & Drug Administration (USFDA) is to manufacture and market Plerixafor Injection of strengths 24 mg/1.2 mL (20 mg/mL), single-dose vial, Aurobindo Pharma said in a regulatory filing.

Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM), the company said.

The product is expected to be launched this month.

>>Go to Mainboard IPOs Section: Click
>>Get Good Staff or Job, Click: Staffavailable.com
>>Interested in Used Automobiles or vintage cars? Click: BigGaddi.com
>>Get solid Guidance on Mutual fund Investments, Click: ChanakyaMFGuidance.com
>>Study Stock Research Reports, Click: AnalysisLibrary.com
>>Interested in Crossword Puzzles? Click: Magajmari.com